Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Neurology · Chronic Inflammatory Demyelinating Polyneuropathy

Understanding Subtypes and Biological Variants

At a Glance

CIDP has several clinical patterns, including typical, MADSAM, DADS, pure motor, pure sensory, and focal forms. Identifying the pattern and checking for look-alike disorders or autoimmune nodopathies can guide testing and treatment, but a subtype can change over time.

While CIDP is often discussed as a single disease, it is actually a collection of related conditions. Understanding the specific “flavor” of CIDP you have is critical because it tells your doctors how your disease might progress and which treatments are most likely to work [1]. Keep in mind that variants can evolve over time, and a subtype is a starting point, not a guarantee of how your condition will behave.

The Biology: Who is Attacking?

In typical CIDP, the body’s immune cells—specifically macrophages—attack and strip away the myelin sheath (the insulation) from your nerves [2]. This causes the electrical signals to leak out or slow down.

However, researchers have recently discovered a distinct group of conditions called Autoimmune Nodopathies. In these cases, the attack is not a broad stripping of insulation but a highly targeted strike by antibodies against the Nodes of Ranvier [3]. These nodes are the tiny gaps in the insulation that allow electrical signals to “hop” quickly down the nerve. Because the mechanism is different, these “nodopathies” may respond poorly to standard treatments like IVIg and specialists may consider different medications like rituximab off-label [4][5].

The CIDP Variants

The 2021 EAN/PNS guidelines recognize several distinct subtypes based on where and how the symptoms appear [6]:

  • Typical CIDP: Symmetrical weakness and sensory loss in both the arms and legs, affecting both the large muscles near the trunk and the small muscles in the hands and feet [7].
  • MADSAM (Lewis-Sumner Syndrome): This version is asymmetric, meaning it might affect one arm or one leg much more than the other. It often involves the nerves in the arms first and can sometimes affect the nerves in the face or eyes (cranial nerves) [8].
  • DADS (Distal CIDP): The symptoms are concentrated mostly in the hands and feet. Because this pattern can look like a different disease called anti-MAG neuropathy, doctors will often run extra blood tests to rule that out [9].
  • Pure Motor or Pure Sensory: Some patients have significant weakness with no sensory symptoms (Pure Motor), while others have only numbness and balance issues with no weakness (Pure Sensory) [10][11].
  • Focal CIDP: This is rare and involves only a single nerve or a specific cluster of nerves (a plexus) in one limb [12].

Identifying “Look-Alike” Conditions

Because the symptoms of CIDP overlap with many other diseases, your doctor must carefully rule out “mimics.” This is why your diagnostic process likely involved many tests.

Condition Why it is confused with CIDP Key Differences
ALS (Lou Gehrig’s) Causes progressive muscle weakness and wasting [13]. ALS affects the brain’s “command” nerves as well; it does not cause the sensory numbness found in most CIDP [13].
CMT (Hereditary) A genetic disorder causing long-term weakness and foot deformities [14]. CMT usually begins in childhood or early adulthood (though adult-onset can happen) and progresses much more slowly over decades [14].
Anti-MAG Neuropathy Causes a very similar “distal” pattern of numbness and gait issues [15]. This is caused by a specific antibody (anti-MAG) and usually responds poorly to the standard steroids used for CIDP [16].
MMN (Multifocal Motor Neuropathy) Causes asymmetric weakness, often in the hands [17]. MMN is primarily motor; while mild subjective sensory complaints can occur, significant objective sensory loss makes MMN less likely [18].
POEMS Syndrome A rare blood disorder that causes nerve damage [19]. POEMS involves other systems, often causing skin changes, organ enlargement, or bone lesions [20].

Knowing your subtype helps you and your doctor set realistic expectations. For example, while Pure Motor CIDP is often treated first with IVIg because steroids can sometimes make it worse, MADSAM might require a more tailored approach because it can be more resistant to standard therapy [1][21]. Tests for specific antibodies are specialized, interpreted in the clinical context, and not required for every person diagnosed with typical CIDP.

Common questions in this guide

Why do doctors identify the specific type of CIDP I have?
CIDP can follow different patterns, including typical, MADSAM, DADS, pure motor, pure sensory, and focal forms. The pattern helps your care team assess how the illness may behave and choose treatments to consider, but it is not a guarantee and can change over time.
What is an autoimmune nodopathy, and is it the same as CIDP?
An autoimmune nodopathy is a related immune nerve disorder in which antibodies target the nodes of Ranvier, the small gaps that help nerve signals travel. Typical CIDP involves immune cells damaging the myelin covering of nerves. Because the targets differ, IVIg may work less well for nodopathies, and a specialist may consider rituximab off-label.
What does MADSAM, or Lewis-Sumner syndrome, look like?
MADSAM is a CIDP variant that usually causes weakness or sensory loss on one side more than the other, often beginning in an arm. It can sometimes involve nerves serving the face or eyes and may need a more individualized treatment plan.
Why might someone with distal CIDP need an anti-MAG test?
Distal CIDP mainly affects the hands and feet, a pattern that can resemble anti-MAG neuropathy. Doctors may order blood tests for the anti-MAG antibody to help distinguish these conditions because their treatments and expected responses can differ.
How do doctors rule out conditions that look like CIDP?
Doctors compare your symptom pattern with a neurologic examination, nerve conduction study, and targeted blood or antibody tests. They may use these findings to distinguish CIDP from ALS, inherited CMT, anti-MAG neuropathy, multifocal motor neuropathy, or POEMS syndrome.
Does a pure motor or pure sensory pattern change CIDP treatment?
It can. Pure motor CIDP is often treated first with IVIg because corticosteroids may make weakness worse, while the best approach for pure sensory disease depends on the full clinical and test findings. Your neurologist should individualize the choice rather than relying on the subtype alone.
Should everyone with CIDP have antibody testing for nodopathy?
Not necessarily. Tests for antibodies such as anti-NF155, anti-CNTN1, or anti-CASPR1 are specialized, and they are not required for every person with typical CIDP. A neurologist can decide whether testing is useful based on your clinical pattern and treatment response.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on the 2021 EAN/PNS guidelines, which CIDP variant best describes my clinical presentation?
  2. 2.Have I been tested for autoimmune nodopathy antibodies like anti-NF155, anti-CNTN1, or anti-CASPR1, and is that appropriate for my case?
  3. 3.If my symptoms are purely motor or purely sensory, how does that change the decision between starting with IVIg versus corticosteroids?
  4. 4.Are there specific findings on my nerve conduction study, like 'conduction blocks' or 'temporal dispersion,' that help rule out hereditary conditions?
  5. 5.What objective tests will we use to distinguish between a CIDP relapse and the slow progression of a look-alike condition?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision.

    Van den Bergh PYK, van Doorn PA, Hadden RDM, et al.

    European journal of neurology 2021; (28(11)):3556-3583 doi:10.1111/ene.14959.

    PMID: 34327760
  2. 2

    Immune-Mediated Neuropathies: Pathophysiology and Management.

    Shastri A, Al Aiyan A, Kishore U, Farrugia ME

    International journal of molecular sciences 2023; (24(8)) doi:10.3390/ijms24087288.

    PMID: 37108447
  3. 3

    [Cutting edge of diagnosis and treatment for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) based on the EAN/PNS guideline 2021].

    Kuwabara S

    Rinsho shinkeigaku = Clinical neurology 2024; (64(5)):321-325 doi:10.5692/clinicalneurol.cn-001937.

    PMID: 38644208
  4. 4

    Clinical features and treatment response of anti-Neurofascin 155 antibody-positive neuropathy in neurological Institute of Thailand.

    Suanprasert N, Sinthuwong C, Apiwattanakul M, Hanchaiphiboolkul S

    Journal of neuroimmunology 2026; (418()):578959 doi:10.1016/j.jneuroim.2026.578959.

    PMID: 42173004
  5. 5

    Advances in the treatment of autoimmune nodopathy: based on treatment strategies of CIDP.

    Pang ZD, Sun H, Wei XJ, et al.

    Frontiers in immunology 2026; (17()):1735745 doi:10.3389/fimmu.2026.1735745.

    PMID: 41890726
  6. 6

    Tips in navigating the diagnostic complexities of chronic inflammatory demyelinating polyradiculoneuropathy.

    Lewis RA, van Doorn PA, Sommer C

    Journal of the neurological sciences 2022; (443()):120478 doi:10.1016/j.jns.2022.120478.

    PMID: 36368137
  7. 7

    Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Its Variants.

    Gwathmey K

    Continuum (Minneapolis, Minn.) 2020; (26(5)):1205-1223 doi:10.1212/CON.0000000000000907.

    PMID: 33002999
  8. 8

    Comparison of Lewis-Sumner syndrome with chronic inflammatory demyelinating polyradiculoneuropathy patients in a tertiary care centre.

    Fargeot G, Maisonobe T, Psimaras D, et al.

    European journal of neurology 2020; (27(3)):522-528 doi:10.1111/ene.14101.

    PMID: 31574194
  9. 9

    Treatment Approaches for Atypical CIDP.

    Menon D, Katzberg HD, Bril V

    Frontiers in neurology 2021; (12()):653734 doi:10.3389/fneur.2021.653734.

    PMID: 33790853
  10. 10

    Motor chronic inflammatory demyelinating polyneuropathy (CIDP) in 17 patients: Clinical characteristics, electrophysiological study, and response to treatment.

    Pegat A, Boisseau W, Maisonobe T, et al.

    Journal of the peripheral nervous system : JPNS 2020; (25(2)):162-170 doi:10.1111/jns.12380.

    PMID: 32364302
  11. 11

    Impact of 2021 European Academy of Neurology/Peripheral Nerve Society diagnostic criteria on diagnosis and therapy of chronic inflammatory demyelinating polyradiculoneuropathy variants.

    De Lorenzo A, Liberatore G, Doneddu PE, et al.

    European journal of neurology 2024; (31(4)):e16190 doi:10.1111/ene.16190.

    PMID: 38165011
  12. 12

    Focal chronic inflammatory demyelinating polyradiculoneuropathy: Onset, course, and distinct features.

    Benoit C, Svahn J, Debs R, et al.

    Journal of the peripheral nervous system : JPNS 2021; (26(2)):193-201 doi:10.1111/jns.12438.

    PMID: 33660880
  13. 13

    Distinguishing Chronic Inflammatory Demyelinating Polyneuropathy From Mimic Disorders: The Role of Statistical Modeling.

    Swart G, Skolka MP, Shelly S, et al.

    Journal of the peripheral nervous system : JPNS 2025; (30(1)):e12682 doi:10.1111/jns.12682.

    PMID: 39801067
  14. 14

    Charcot-Marie-Tooth type 4 C misdiagnosed as CIDP: electrodiagnostic pitfalls and genetic confirmation.

    Okhovat AA, Shahriyari H, Ghasemi A, et al.

    Neurogenetics 2026; (27(1)).

    PMID: 42377577
  15. 15

    Anti-MAG neuropathy: historical aspects, clinical-pathological correlations, and considerations for future therapeutical trials.

    Latov N, Brannagan TH, Sander HW, Gondim FAA

    Arquivos de neuro-psiquiatria 2024; (82(6)):1-7 doi:10.1055/s-0043-1777728.

    PMID: 38325389
  16. 16

    Optimizing Anti-Myelin-Associated Glycoprotein and IgM-Gammopathy Testing for Neuropathy Treatment Evaluation.

    Klein CJ, Triplett JD, Murray DL, et al.

    Neurology 2024; (103(11)):e210000 doi:10.1212/WNL.0000000000210000.

    PMID: 39499873
  17. 17

    Nerve Pathology Distinguishes Focal Motor Chronic Inflammatory Demyelinating Polyradiculoneuropathy From Multifocal Motor Neuropathy.

    Tracy JA, Taylor BV, Kiernan M, et al.

    Journal of clinical neuromuscular disease 2020; (22(1)):1-10 doi:10.1097/CND.0000000000000279.

    PMID: 32833719
  18. 18

    Nerve Conduction Abnormalities Beyond Conduction Block in Multifocal Motor Neuropathy. Impact on Diagnostic Criteria Accuracy.

    Doneddu PE, Gallo C, Falzone Y, et al.

    European journal of neurology 2025; (32(9)):e70300 doi:10.1111/ene.70300.

    PMID: 40984777
  19. 19

    CIDP mimics: a case series.

    Moshe-Lilie O, Ensrud E, Ragole T, et al.

    BMC neurology 2021; (21(1)):94 doi:10.1186/s12883-021-02118-7.

    PMID: 33639867
  20. 20

    Paraproteinemia and neuropathy.

    Koike H, Katsuno M

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2021; (42(11)):4489-4501 doi:10.1007/s10072-021-05583-7.

    PMID: 34529193
  21. 21

    Diagnosis and treatment response in the asymmetric variant of chronic inflammatory demyelinating polyneuropathy.

    Lucke IM, Wieske L, van der Kooi AJ, et al.

    Journal of the peripheral nervous system : JPNS 2019; (24(2)):174-179 doi:10.1111/jns.12325.

    PMID: 31090121

This page is for informational purposes only and does not constitute medical advice. A neurologist should interpret your symptoms, antibody tests, and nerve studies when determining the most appropriate diagnosis and treatment.

Get notified when new evidence is published on polyneuropathy, inflammatory demyelinating, chronic.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.